Ryo Kiguchi , Ayano Hata , Satoki Fujita , Yuki Yoshida , Yoshitake Kitanishi , Junichiro Yoshimoto , Aran Tajika , Toshi A. Furukawa
{"title":"使用数字生物标志物预测维持药物治疗缓解抑郁症的症状恶化:一项使用机器学习的预后建模研究。","authors":"Ryo Kiguchi , Ayano Hata , Satoki Fujita , Yuki Yoshida , Yoshitake Kitanishi , Junichiro Yoshimoto , Aran Tajika , Toshi A. Furukawa","doi":"10.1016/j.jad.2025.119703","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Depression is highly recurrent, and predicting relapses in a timely manner is critical. We applied machine learning to predict the worsening of depressive symptoms.</div></div><div><h3>Methods</h3><div>We conducted a 52-week cohort study of patients with recurrent depression on maintenance pharmacotherapy, using a smartphone app and a wearable device. Participants reported their depression level by filling in the Kessler Psychological Distress Scale (K6) every week on the app. We first classified participants based on their lifestyle characteristics. We then applied the leave-one-participant-out cross-validated (LOOCV) XGBoost to predict K6 scores. We also simulated how the model can perform, where the data of a new patient is collected for some time and then added to the existing dataset to predict the new patient's symptom worsening in the future.</div></div><div><h3>Results</h3><div>We analyzed the data from 89 participants (49 males; median age, 44 years). We identified two distinct clusters of participants: participants in Cluster 1 had unstable sleep patterns and spent more time indoors, whereas those in Cluster 2 spent more time working/studying. The straightforward LOOCV performance showed good AUC but low kappa. When we added observations of a new patient for three months, the weighted kappa between the predicted and the observed K6 classes improved to 0.68 (95 % confidence interval: 0.55–0.81) for Cluster 1 and 0.59 (0.48–0.70) for Cluster 2.</div></div><div><h3>Conclusions</h3><div>Subtyping patients by their behavioral patterns and applying machine learning allowed us to build prediction models for depression relapses among patients on maintenance pharmacotherapy.</div></div><div><h3>Funding</h3><div>Shionogi & Co., Ltd.</div></div>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":"389 ","pages":"Article 119703"},"PeriodicalIF":4.9000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predicting symptom worsening in remitted depression on maintenance pharmacotherapy using digital biomarkers: A prognostic modeling study using machine learning\",\"authors\":\"Ryo Kiguchi , Ayano Hata , Satoki Fujita , Yuki Yoshida , Yoshitake Kitanishi , Junichiro Yoshimoto , Aran Tajika , Toshi A. Furukawa\",\"doi\":\"10.1016/j.jad.2025.119703\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Depression is highly recurrent, and predicting relapses in a timely manner is critical. We applied machine learning to predict the worsening of depressive symptoms.</div></div><div><h3>Methods</h3><div>We conducted a 52-week cohort study of patients with recurrent depression on maintenance pharmacotherapy, using a smartphone app and a wearable device. Participants reported their depression level by filling in the Kessler Psychological Distress Scale (K6) every week on the app. We first classified participants based on their lifestyle characteristics. We then applied the leave-one-participant-out cross-validated (LOOCV) XGBoost to predict K6 scores. We also simulated how the model can perform, where the data of a new patient is collected for some time and then added to the existing dataset to predict the new patient's symptom worsening in the future.</div></div><div><h3>Results</h3><div>We analyzed the data from 89 participants (49 males; median age, 44 years). We identified two distinct clusters of participants: participants in Cluster 1 had unstable sleep patterns and spent more time indoors, whereas those in Cluster 2 spent more time working/studying. The straightforward LOOCV performance showed good AUC but low kappa. When we added observations of a new patient for three months, the weighted kappa between the predicted and the observed K6 classes improved to 0.68 (95 % confidence interval: 0.55–0.81) for Cluster 1 and 0.59 (0.48–0.70) for Cluster 2.</div></div><div><h3>Conclusions</h3><div>Subtyping patients by their behavioral patterns and applying machine learning allowed us to build prediction models for depression relapses among patients on maintenance pharmacotherapy.</div></div><div><h3>Funding</h3><div>Shionogi & Co., Ltd.</div></div>\",\"PeriodicalId\":14963,\"journal\":{\"name\":\"Journal of affective disorders\",\"volume\":\"389 \",\"pages\":\"Article 119703\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of affective disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165032725011450\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165032725011450","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Predicting symptom worsening in remitted depression on maintenance pharmacotherapy using digital biomarkers: A prognostic modeling study using machine learning
Background
Depression is highly recurrent, and predicting relapses in a timely manner is critical. We applied machine learning to predict the worsening of depressive symptoms.
Methods
We conducted a 52-week cohort study of patients with recurrent depression on maintenance pharmacotherapy, using a smartphone app and a wearable device. Participants reported their depression level by filling in the Kessler Psychological Distress Scale (K6) every week on the app. We first classified participants based on their lifestyle characteristics. We then applied the leave-one-participant-out cross-validated (LOOCV) XGBoost to predict K6 scores. We also simulated how the model can perform, where the data of a new patient is collected for some time and then added to the existing dataset to predict the new patient's symptom worsening in the future.
Results
We analyzed the data from 89 participants (49 males; median age, 44 years). We identified two distinct clusters of participants: participants in Cluster 1 had unstable sleep patterns and spent more time indoors, whereas those in Cluster 2 spent more time working/studying. The straightforward LOOCV performance showed good AUC but low kappa. When we added observations of a new patient for three months, the weighted kappa between the predicted and the observed K6 classes improved to 0.68 (95 % confidence interval: 0.55–0.81) for Cluster 1 and 0.59 (0.48–0.70) for Cluster 2.
Conclusions
Subtyping patients by their behavioral patterns and applying machine learning allowed us to build prediction models for depression relapses among patients on maintenance pharmacotherapy.
期刊介绍:
The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.